As SARS-CoV-2 inhibits IFN-I production, the IFNβ-ACE2 targeting strategy may fulfill these criteria by introducing IFN-β directly to the site of infection by binding to ACE2-tropic viruses, including emergent coronaviruses that represent a clear global threat for future pandemics. Here, ACE2 is linked to infection.